You have read all your free articles, to continue reading subscribe to read the rest of this content.
Moberg Pharma has completed the recruitment of 365 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015. Topline results are expected in theAlready a subscriber…
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone. THEMIS was conducted in over 19,Already a subscriber Login You have read all your…
A team of scientists from San Francisco has found a way to transport medication to fight Alzheimer’s disease through the blood-brain barrier in monkeys without serious side-effects. A Danish PhD student who is participating on the research team, Maria Selch Hersom, from the Department of PharmaAlready a subscriber Login You…
The first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer. The Phase I study is a dose escalation study in patients with advanced cancer and this is the first time ATOR-1017…
